Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists

Michael H. Davidson, Christie M. Ballantyne, Terry A. Jacobson, Vera A. Bittner, Lynne T. Braun, Alan S. Brown, W. Virgil Brown, William C. Cromwell, Ronald B Goldberg, James M. McKenney, Alan T. Remaley, Allan D. Sniderman, Peter P. Toth, Sotirios Tsimikas, Paul E. Ziajka, Kevin C. Maki, Mary R. Dicklin

Research output: Contribution to journalArticle

185 Citations (Scopus)

Abstract

The National Cholesterol Education Program Adult Treatment Panel guidelines have established low-density lipoprotein cholesterol (LDL-C) treatment goals, and secondary non-high-density lipoprotein (HDL)-C treatment goals for persons with hypertriglyceridemia. The use of lipid-lowering therapies, particularly statins, to achieve these goals has reduced cardiovascular disease (CVD) morbidity and mortality; however, significant residual risk for events remains. This, combined with the rising prevalence of obesity, which has shifted the risk profile of the population toward patients in whom LDL-C is less predictive of CVD events (metabolic syndrome, low HDL-C, elevated triglycerides), has increased interest in the clinical use of inflammatory and lipid biomarker assessments. Furthermore, the cost effectiveness of pharmacological intervention for both the initiation of therapy and the intensification of therapy has been enhanced by the availability of a variety of generic statins. This report describes the consensus view of an expert panel convened by the National Lipid Association to evaluate the use of selected biomarkers [C-reactive protein, lipoprotein-associated phospholipase A 2, apolipoprotein B, LDL particle concentration, lipoprotein(a), and LDL and HDL subfractions] to improve risk assessment, or to adjust therapy. These panel recommendations are intended to provide practical advice to clinicians who wrestle with the challenges of identifying the patients who are most likely to benefit from therapy, or intensification of therapy, to provide the optimum protection from CV risk.

Original languageEnglish
Pages (from-to)338-367
Number of pages30
JournalJournal of Clinical Lipidology
Volume5
Issue number5
DOIs
StatePublished - Sep 1 2011

Fingerprint

Lipoproteins
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Therapeutics
HDL Lipoproteins
LDL Cholesterol
Cardiovascular Diseases
Biomarkers
1-Alkyl-2-acetylglycerophosphocholine Esterase
Lipoprotein(a)
Hypertriglyceridemia
Apolipoproteins B
LDL Lipoproteins
C-Reactive Protein
Cost-Benefit Analysis
Triglycerides
Obesity
Cholesterol
Pharmacology
Guidelines

Keywords

  • Apolipoprotein B
  • C-reactive protein
  • Lipoprotein subfractions
  • Lipoprotein(a)
  • Lipoprotein-associated phospholipase A2
  • Low-density lipoprotein particle concentration

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Cite this

Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., ... Dicklin, M. R. (2011). Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology, 5(5), 338-367. https://doi.org/10.1016/j.jacl.2011.07.005

Clinical utility of inflammatory markers and advanced lipoprotein testing : Advice from an expert panel of lipid specialists. / Davidson, Michael H.; Ballantyne, Christie M.; Jacobson, Terry A.; Bittner, Vera A.; Braun, Lynne T.; Brown, Alan S.; Brown, W. Virgil; Cromwell, William C.; Goldberg, Ronald B; McKenney, James M.; Remaley, Alan T.; Sniderman, Allan D.; Toth, Peter P.; Tsimikas, Sotirios; Ziajka, Paul E.; Maki, Kevin C.; Dicklin, Mary R.

In: Journal of Clinical Lipidology, Vol. 5, No. 5, 01.09.2011, p. 338-367.

Research output: Contribution to journalArticle

Davidson, MH, Ballantyne, CM, Jacobson, TA, Bittner, VA, Braun, LT, Brown, AS, Brown, WV, Cromwell, WC, Goldberg, RB, McKenney, JM, Remaley, AT, Sniderman, AD, Toth, PP, Tsimikas, S, Ziajka, PE, Maki, KC & Dicklin, MR 2011, 'Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists', Journal of Clinical Lipidology, vol. 5, no. 5, pp. 338-367. https://doi.org/10.1016/j.jacl.2011.07.005
Davidson, Michael H. ; Ballantyne, Christie M. ; Jacobson, Terry A. ; Bittner, Vera A. ; Braun, Lynne T. ; Brown, Alan S. ; Brown, W. Virgil ; Cromwell, William C. ; Goldberg, Ronald B ; McKenney, James M. ; Remaley, Alan T. ; Sniderman, Allan D. ; Toth, Peter P. ; Tsimikas, Sotirios ; Ziajka, Paul E. ; Maki, Kevin C. ; Dicklin, Mary R. / Clinical utility of inflammatory markers and advanced lipoprotein testing : Advice from an expert panel of lipid specialists. In: Journal of Clinical Lipidology. 2011 ; Vol. 5, No. 5. pp. 338-367.
@article{57df7f8bd7504826a0dd3aced0055c17,
title = "Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists",
abstract = "The National Cholesterol Education Program Adult Treatment Panel guidelines have established low-density lipoprotein cholesterol (LDL-C) treatment goals, and secondary non-high-density lipoprotein (HDL)-C treatment goals for persons with hypertriglyceridemia. The use of lipid-lowering therapies, particularly statins, to achieve these goals has reduced cardiovascular disease (CVD) morbidity and mortality; however, significant residual risk for events remains. This, combined with the rising prevalence of obesity, which has shifted the risk profile of the population toward patients in whom LDL-C is less predictive of CVD events (metabolic syndrome, low HDL-C, elevated triglycerides), has increased interest in the clinical use of inflammatory and lipid biomarker assessments. Furthermore, the cost effectiveness of pharmacological intervention for both the initiation of therapy and the intensification of therapy has been enhanced by the availability of a variety of generic statins. This report describes the consensus view of an expert panel convened by the National Lipid Association to evaluate the use of selected biomarkers [C-reactive protein, lipoprotein-associated phospholipase A 2, apolipoprotein B, LDL particle concentration, lipoprotein(a), and LDL and HDL subfractions] to improve risk assessment, or to adjust therapy. These panel recommendations are intended to provide practical advice to clinicians who wrestle with the challenges of identifying the patients who are most likely to benefit from therapy, or intensification of therapy, to provide the optimum protection from CV risk.",
keywords = "Apolipoprotein B, C-reactive protein, Lipoprotein subfractions, Lipoprotein(a), Lipoprotein-associated phospholipase A2, Low-density lipoprotein particle concentration",
author = "Davidson, {Michael H.} and Ballantyne, {Christie M.} and Jacobson, {Terry A.} and Bittner, {Vera A.} and Braun, {Lynne T.} and Brown, {Alan S.} and Brown, {W. Virgil} and Cromwell, {William C.} and Goldberg, {Ronald B} and McKenney, {James M.} and Remaley, {Alan T.} and Sniderman, {Allan D.} and Toth, {Peter P.} and Sotirios Tsimikas and Ziajka, {Paul E.} and Maki, {Kevin C.} and Dicklin, {Mary R.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.jacl.2011.07.005",
language = "English",
volume = "5",
pages = "338--367",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Clinical utility of inflammatory markers and advanced lipoprotein testing

T2 - Advice from an expert panel of lipid specialists

AU - Davidson, Michael H.

AU - Ballantyne, Christie M.

AU - Jacobson, Terry A.

AU - Bittner, Vera A.

AU - Braun, Lynne T.

AU - Brown, Alan S.

AU - Brown, W. Virgil

AU - Cromwell, William C.

AU - Goldberg, Ronald B

AU - McKenney, James M.

AU - Remaley, Alan T.

AU - Sniderman, Allan D.

AU - Toth, Peter P.

AU - Tsimikas, Sotirios

AU - Ziajka, Paul E.

AU - Maki, Kevin C.

AU - Dicklin, Mary R.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - The National Cholesterol Education Program Adult Treatment Panel guidelines have established low-density lipoprotein cholesterol (LDL-C) treatment goals, and secondary non-high-density lipoprotein (HDL)-C treatment goals for persons with hypertriglyceridemia. The use of lipid-lowering therapies, particularly statins, to achieve these goals has reduced cardiovascular disease (CVD) morbidity and mortality; however, significant residual risk for events remains. This, combined with the rising prevalence of obesity, which has shifted the risk profile of the population toward patients in whom LDL-C is less predictive of CVD events (metabolic syndrome, low HDL-C, elevated triglycerides), has increased interest in the clinical use of inflammatory and lipid biomarker assessments. Furthermore, the cost effectiveness of pharmacological intervention for both the initiation of therapy and the intensification of therapy has been enhanced by the availability of a variety of generic statins. This report describes the consensus view of an expert panel convened by the National Lipid Association to evaluate the use of selected biomarkers [C-reactive protein, lipoprotein-associated phospholipase A 2, apolipoprotein B, LDL particle concentration, lipoprotein(a), and LDL and HDL subfractions] to improve risk assessment, or to adjust therapy. These panel recommendations are intended to provide practical advice to clinicians who wrestle with the challenges of identifying the patients who are most likely to benefit from therapy, or intensification of therapy, to provide the optimum protection from CV risk.

AB - The National Cholesterol Education Program Adult Treatment Panel guidelines have established low-density lipoprotein cholesterol (LDL-C) treatment goals, and secondary non-high-density lipoprotein (HDL)-C treatment goals for persons with hypertriglyceridemia. The use of lipid-lowering therapies, particularly statins, to achieve these goals has reduced cardiovascular disease (CVD) morbidity and mortality; however, significant residual risk for events remains. This, combined with the rising prevalence of obesity, which has shifted the risk profile of the population toward patients in whom LDL-C is less predictive of CVD events (metabolic syndrome, low HDL-C, elevated triglycerides), has increased interest in the clinical use of inflammatory and lipid biomarker assessments. Furthermore, the cost effectiveness of pharmacological intervention for both the initiation of therapy and the intensification of therapy has been enhanced by the availability of a variety of generic statins. This report describes the consensus view of an expert panel convened by the National Lipid Association to evaluate the use of selected biomarkers [C-reactive protein, lipoprotein-associated phospholipase A 2, apolipoprotein B, LDL particle concentration, lipoprotein(a), and LDL and HDL subfractions] to improve risk assessment, or to adjust therapy. These panel recommendations are intended to provide practical advice to clinicians who wrestle with the challenges of identifying the patients who are most likely to benefit from therapy, or intensification of therapy, to provide the optimum protection from CV risk.

KW - Apolipoprotein B

KW - C-reactive protein

KW - Lipoprotein subfractions

KW - Lipoprotein(a)

KW - Lipoprotein-associated phospholipase A2

KW - Low-density lipoprotein particle concentration

UR - http://www.scopus.com/inward/record.url?scp=80053914425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053914425&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2011.07.005

DO - 10.1016/j.jacl.2011.07.005

M3 - Article

C2 - 21981835

AN - SCOPUS:80053914425

VL - 5

SP - 338

EP - 367

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 5

ER -